Design of a RANK-Mimetic Peptide Inhibitor of Osteoclastogenesis with Enhanced RANKL-Binding Affinity

about

Porphyrin Derivatives Inhibit the Interaction between Receptor Activator of NF-κB and Its Ligand.

P2860

Q47834751-5A87CD2C-405F-4240-BFFF-C4999BDD1251

P2860

Design of a RANK-Mimetic Peptide Inhibitor of Osteoclastogenesis with Enhanced RANKL-Binding Affinity

Item

http://www.wikidata.org/entity/Q36835372

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Design of a RANK-Mimetic Pepti ...... nhanced RANKL-Binding Affinity

@en

type

Item

label

Design of a RANK-Mimetic Pepti ...... nhanced RANKL-Binding Affinity

@en

prefLabel

Design of a RANK-Mimetic Pepti ...... nhanced RANKL-Binding Affinity

@en

P1476

Design of a RANK-Mimetic Pepti ...... nhanced RANKL-Binding Affinity

@en

P2093

Ambarnil Ghosh

http://www.w3.org/2001/XMLSchema#string

Hai Minh Ta

http://www.w3.org/2001/XMLSchema#string

Hye-Yeon Hwang

http://www.w3.org/2001/XMLSchema#string

Hyunju Kim

http://www.w3.org/2001/XMLSchema#string

Jeonghwan Hur

http://www.w3.org/2001/XMLSchema#string

Kabsun Kim

http://www.w3.org/2001/XMLSchema#string

Kyeong Kyu Kim

http://www.w3.org/2001/XMLSchema#string

Nacksung Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Structure-based development of a receptor activator of nuclear factor- B ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

RANKL-RANK signaling in osteoclastogenesis and bone disease

Comparative protein structure modeling using Modeller

Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability

Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis.

Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.

Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL.

Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients.

Rosetta FlexPepDock web server--high resolution modeling of peptide-protein interactions

P304

316-321

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.14348/MOLCELLS.2016.2286

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

296481371

http://www.w3.org/2001/XMLSchema#string

P698

26923188

http://www.w3.org/2001/XMLSchema#string

P932

4844938

http://www.w3.org/2001/XMLSchema#string

Design of a RANK-Mimetic Peptide Inhibitor of Osteoclastogenesis with Enhanced RANKL-Binding Affinity

about

P2860

P2860

Design of a RANK-Mimetic Peptide Inhibitor of Osteoclastogenesis with Enhanced RANKL-Binding Affinity

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932